STK Markets have been appointed as Corporate Adviser to Foresta Group Holdings Limited (ASX:FGH)

Foresta has developed a proprietary process that naturally extracts high-value products from pine trees and stumps. It is building a plant in New Zealand where the company will manufacture pine chemicals and pine wood pellets that will be a direct coal replacement. 

Foresta is completely transforming the energy industry by providing a clean energy source where “net zero” and Carbon Credits offer additional value.

Foresta offer a desirable sale partner to Pine plantation owners because they remove the entire tree and stump – whereas standard timber purchasers leave not only all stumps but many trees behind. 

With the trial/ demonstration facility successfully completed and their process proven, Foresta has signed Supply and Offtake Agreements enabling it to progress towards constructing their first processing plant to satisfy strong product demand with an expansion model operating multiple processing plants globally. Foresta plan to build 9 plants in New Zealand through a modular roll-out process.

Foresta is undertaking a capital raise of $1.5m to accelerate the torrefied pellets and wood chemical manufacturing facility project in New Zealand, and to provide additional working capital. 

To learn more about this investment opportunity or if you have any questions, please don't hesitate to Sean Sandilands at 0412 166 471 or sean@stkmarkets.com

WHOLESALE AND SOPHISTICATED INVESTORS ONLY

Overview

Aegros, an Australian clinical-stage biopharmaceutical company leader in the development and manufacture of plasma derived medicinal products (PDMPs), today announced positive top-line interim results from its CHAT clinical trial.

Top-line interim results indicate that Aegros’ COVID-19 hyperimmune provides higher levels of antibodies compared to high-titer convalescent plasma. These results are in line with Aegros’ pre-clinical expectations.

CHAT compared Aegros’ COVID-19 hyperimmune to COVID-19 convalescent plasma. The hyperimmune was manufactured using Aegros’ patented Haemafrac® process. A hyperimmune is an intravenous immunoglobulin rich in antibodies that can provide passive immunity for immunocompromised individuals.

The key findings of CHAT include:
The mean maximum antibody levels (Cmax), measured using the Abbott AdviseDx SARS-CoV-2 antibody assay system for the convalescent plasma (n=11) and immunoglobulin (n=11) arms was 154.7 (+ 43.0) AU/mL and 685 (+ 224.1) AU/mL respectively – a fourfold increase over convalescent plasma.

The safety profiles of both convalescent plasma and immunoglobulin were as expected.
These trial results are incredibly important for many Australians unable to benefit from the current COVID-19 vaccines because of with underlying conditions such as immunodeficiency, certain cancers, and rare diseases..
“These results mark a significant milestone in our ongoing commitment to advancing healthcare and addressing the unmet needs of immunocompromised individuals whose responses to vaccination are less than optimal,” said Mr John Manusu, Aegros Cofounder and Managing Director.

“By announcing these results today, Aegros signals that it is an Australian manufacturer of plasma medicines that has achieved what many have failed to do; make and test a hyperimmune against SARS-CoV-2 to address a critical need amongst those who cannot benefit from a vaccine,”

“This result shows that Haemafrac®, our cutting-edge process of fractionation, not only meets the specifications required for an immunoglobulin product but can successfully provide a higher level of passive immunity against COVID-19 disease than convalescent plasma,” said Professor Hari Nair, Cofounder and Executive Chair Aegros.

Please see attached Aegros company press release for further information.

Institutional roadshow in Singapore: 
In Mid-October and the end of November Aegros were in Singapore to introduce its plasma fractionation technology and South East Asian plan to major institutions. The feedback has been very positive with strong interest to participate in the current $18 per share investment opportunities. Further research is being conducted by some of South East Asia largest funds.

There was and is much interest in Aegros Asian marketing strategy because this market is grossly undersupplied with plasma derived medicinal products (PDMPs). Currently, only Aegros Haemafrac® technology is able to process Asian plasma (currently it is being discarded) which will be done in it's 1million litre faciltiy to be funded by the Royal Group of Cambodia.

As stated previously we are pleased to inform you that STK Markets is currently facilitating a private placement to raise $10 million at a price of $18 per share. As per the video we have had significant interest in South East Asia due to the fact the Royal Group has underwritten a US$400m investment in the fully funded 1m litre facility to be built in Singapore and the pack and fill facility in Cambodia.

This is at a fully diluted valuation of AUD $1,280m which is at a discount to the last valuation point which we expect will have risen once again following this Joint Venture agreement and the preliminary results of the clinical trail. This raise has been going as planned and we have increased the value to $30 Mil to provide an opportunity for our Australian and South East Asia investors.

The funds raised through this placement will be utilized to support working capital requirements and finance the upgrade of their Macquarie Park facility from 30,000L to 100,000 litres per annum. 

 Aegros bonus offer to existing $5 options holders.
Aegros options that expire on 31st December 2023 $5 or the end of this month must be exercised by this date or they will be forfitted. If you have any inquiries or require further clarification, please do not hesitate to contact Sean at 0412 166 471 or via email at sean@stkmarkets.com. Kindly note that this offer is only available to wholesale or sophisticated investors.

About Tru Recognition

TRU Recognition (“TRU Rec) is the AI company behind the camera’s found in shopping centres, airports, ports, hospitals, casino’s and what seems everywhere else. 

TRU Rec transforms, scales and simplifies camera infrastructure that has already been installed and currently in use, or is ready for installation. Their proprietary platform provides unlimited use-cases for companies and enables organisations to make accurate data-driven decisions from the visual information they are capturing. 

TRU Recognition renders single-use video surveillance platforms obsolete by enabling vision streams to be split up to 64 times, transforming visual data into actionable insights. I see TRU rec as the smart-TV with all the options vs existing options that offer just a single TV channel.
Trialled, proven, now deployed and generating revenue from some heavyweight clients such as Home Affairs, Casino’s and local councils TRU Rec is ready to scale up in a big way.

While I understand the functionality of these devices I personally don’t enjoy the creep of them into our lives. It is at least comforting that I can invest in and stay close to the company who are at the front line of what happens behind the camera with our information. Reassuringly I can confirm that the directors and management of TRU Rec have a strong moral compass about this and have strived to ensure personal information is anonymised, protected and not misused. Information regarding this aspect in contained in the attached Term Sheet information document.

TRU Rec are raising $2.4m offering a Convertible Note at 10%p.a interest. They are also proving 1st Ranking security over FY24 & FY25 R&D Claims, registered PPSR(s) to noteholders. Offer opens today and closes on Wednesday, funds then due Friday the 22nd.
Information and details below and in the attachment. Further information can be supplied upon signing an NDA- understandably there is a lot of IP in this one.

The Investment Opportunity

Tru Recognition are raising up to $2.4 million via a convertible note based on a conversion price of $0.20 with a pre-money valuation of $28m or at a 10% discount to the next capital raise round if that round is below $0.20 per share.

The important thing to note here is that these notes are secured against the future RND refunds from the government hence reducing the risk for investors but still paying an attractive yield of 10%.

Given that breakeven is potentially next year and revenue is growing as planned the opportunity to invest at this early stage is not expected again, if at all at these levels.  

An exit through public listing or trade sale is most likely and we note the strong possibility of attracting strategic investment from customers who don't want to be left behind with the current 'old-school' sub-optimal approach of having 15 platforms when their only needs one. 

This is a dream for any CFO wanting to cut cost and in this environment where everything we are reading involves cost blow outs Tru Recognition could be very special for your portfolio.

To learn more about this investment opportunity or if you have any questions, please don't hesitate to Sean Sandilands at 0412 166 471 or on sean@stkmarkets.com 

WHOLESALE AND SOPHISTICATED INVESTORS ONLY

Big pharma giants are jumping onboard RoseRx for early-year surge. It's the last time we'll see this low valuation.

High Level Summary

• New substantial contracts closed in last 5 months which take Rose Rx to almost cash flow +ve:-
• $1.73m first year revenue
• Gross margins increased from 65% to 80%
• Secured first channel partner (key to enterprise sales)
• $2.2m in 10+ contracts already closed for 2024 with ‘Tier 1’ pharma companies
• Highly successful pilot in Australia launching the expansion to multiple jurisdictions (Europe, SE Asia)
• Low cash burn and EBITDA positive for 2024

A quick re-cap on the problem & solution

Pharma/life science is spending more on marketing than R&D ($214b annually), predominantly on ‘old school’ techniques (think ‘door to door’ drug reps) with low and uncertain returns.  One of the last frontiers and industries to adopt digital performance-based marketing.  

The post COVID world turned healthcare digital, including all demographics of consumers and health care professionals.  The starting place for most consumers now (and even HCP’s) is the internet.  However, pharma hasn’t been able to adapt and respond.  In short, they can’t – due to strict compliance and a desperate lack of experience in the space. 

Enter RoseRx.  They took their many years of experience in direct-to-consumer digital healthcare delivering over 500,000 treatments in two years (achieving $5m ARR), and developed a software-as-a-service (SaaS) platform for big pharma to connect to their future patients and accelerate sales (just like nearly every other industry has managed to do).

It's been tested, proven and works extremely well which is why we are now seeing contract renewal and expansion with the likes of Novo Nordisk; Organon; Jazz; iNova; MSD, Novartis, Bristol Myers Squibb; & Viatris (Pfizer) in the areas of erectile dysfunction (including a very well-know brand name we cannot name, psychiatry, neuropathic pain, women’s health, infectious disease, and weight loss). 

Opportunity

Due to the earlier than expected locking in of contracts and revenue, not as much capital is required.  Whilst we are raising up to $1.2m, RoseRx now needs less and we have filled 35% of the raise and are moving to close the opportunity on 1 December.

In a market where many unlisted companies either fail to raise any funds or haven’t attempted at all, we’re very happy with the commitment.

We’ve convinced management & the Board to leave the raise open until 1 December 2023 at the same valuation as pre locked in contracts and revenue, back in May 2023.

At a pre-money valuation of $7.3m, that is only 1.5 times forecast 2024 revenue (nearly half of which is already locked in as at November 2023 with more imminent).  Given the massive potential upside, the risk-reward scenario is now looking very attractive.

In short:

• We have the tech, IP and first-mover advantage
• We have the experienced team
• We have the big clients and results
• We have locked-in revenue and momentum
• We have the credibility on the capital table (Breyer Capital; Artesian; Vulpes; Spring Capital)
• We have much less risk at the same low valuation
• We have exit-strategies of trade buy-out or IPO

For any inquiries, please contact Sean Sandilands on 0412 166 471 or Shane White on 0439 485 428.

Bids close 5pm Friday 1 December 2023. WHOLESALE AND SOPHISTICATED INVESTORS ONLY

Gathar is a double-sided marketplace platform that seamlessly connects those who love to cook with those who love to entertain, but don’t love the hard work that comes with it. Gathar is a high-growth start up and have been operating in the catering and private chef industry since 2018.

Gathar creates dining experiences of all shapes and sizes, from private chef at home dinners-for-two through to corporate events for 20,000+ people.
Your Gathar Culinarian will come to your home, office, venue, or holiday property with all the ingredients ready to cook, serve and clean up, leaving you and your guests to simply enjoy.

Gathar was incorporated in 2017 and launched their platform in Queensland in 2018. Since then, Gathar has grown to become one of the largest and most trusted catering platforms in Australia, with a community of 400+ suppliers who have earned us 1000+ 5-star reviews. 

If you are interested in learning more contact us at sean@stkmarkets.com

Tungsten Metals Group Limited (TMG) is a producer of high- quality Ferrotungsten (FeW). It owns and operates the largest and most advanced processing plant outside of China, located in Vĩnh Bảo in Vietnam, 75km South East of Hanoi. The plant can process up 4,000 tonnes of FeW per annum with production capacity of 16 tonnes per day. TMG buys Tungsten concentrate from global producers, ships to its plant and processes for sale with the pre-ordered off-take agreement. 

TMG plans to be a high cash-generating company and has the intention to become a dividend-paying stock.

If you are interested in learning more contact us at sean@stkmarkets.com